



## Entasis Therapeutics to Participate in the 2021 Webbush PacGrow Healthcare Conference

August 4, 2021

WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of management will participate in the Webbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021.

### Webbush PacGrow 2021 Virtual Healthcare Conference

Format: Panel presentation (Infectious Personality) and one-on-one investor meetings

Presentation Date & Time: Wednesday, August 11, 2021, at 4:40 p.m. ET

The webcast of the Webbush presentation will be accessible in the [News & Events](#) section of the Entasis website at <https://www.entasistx.com/>.

### About Entasis

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting *Acinetobacter baumannii* infections), zoliflodacin (targeting *Neisseria gonorrhoeae* infections), ETX0282CPDP (targeting *Enterobacteriaceae* infections) and ETX0462 (targeting *Pseudomonas* infections). For more information, visit [www.entasistx.com](http://www.entasistx.com).

### Company Contact:

Kyle Dow  
Entasis Therapeutics  
(781) 810-0114  
[kyle.dow@entasistx.com](mailto:kyle.dow@entasistx.com)

### Investor Relations Contact:

Bruce Mackle  
LifeSci Advisors  
(929) 469-3859  
[bmackle@lifesciadvisors.com](mailto:bmackle@lifesciadvisors.com)



Source: Entasis Therapeutics Holdings Inc.